These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26867764)

  • 1. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
    Nielsen KV; Ejlertsen B; Møller S; Jørgensen JT; Knoop A; Knudsen H; Mouridsen HT
    Acta Oncol; 2008; 47(4):725-34. PubMed ID: 18465341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
    Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ
    J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
    García-Caballero T; Prieto O; Vázquez-Boquete A; Gude F; Viaño P; Otero M; Curiel T; Fernández-Rodríguez B; Parrado C; Fraga M; Antúnez JR
    Breast Cancer Res Treat; 2014 Jan; 143(1):81-9. PubMed ID: 24292870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
    J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
    Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
    Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.